Sarepta Therapeutics Annual Income Statement (NASDAQ:SRPT)

Add to My Stocks
$36.26 $1.54 (4.44%) SRPT stock closing price Apr 28, 2017 (Closing)

Fundamental analysis of SRPT stock involves analyzing its financial statements, apart from checking the Sarepta Therapeutics stock price The income statement is a summary of the revenue, expenses and profitability (shown as Net Income) or lack of it. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the SRPT stock is bound to reflect the impact of the YoY growth of $4.17M. The Sarepta Therapeutics profit and loss statement for 2016 shows a profit of $-267.26M. Profits have reduced from $-220.03M YoY. Apart from this an investor should also check Sarepta Therapeutics assets and Sarepta Therapeutics free cash flow. Sarepta Therapeutics revenue for 2016 is $5.42M. View revenue and profit details for latest and last 10 financial years.

show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Sarepta Therapeutics Net Sales or Revenues
Cost Of Goods Sold (COGS)0.13M---------
Sarepta Therapeutics Gross Profit
Research & Development Expense188.27M146.39M94.23M72.9M52.4M66.86M35.97M24.39M38.91M34.76M
Selling General & Admin Expense83.74M75.04M49.31M31.59M14.63M16.05M14.38M8.69M9.79M9.33M
Income Before Depreciation Depletion Amortization-266.73M-220.18M-133.78M-90.28M-29.7M-35.92M-20.93M-15.5M-27.45M-33.1M
Depreciation Depletion Amortization----------
Non Operating Income-0.53M0.15M-2M-21.7M-91.58M33.6M-11.24M-9.65M3.5M5.93M
Interest Expense----------
Sarepta Therapeutics Pretax Income
Provision for Income Taxes----------
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-267.26M-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Extraordinary Items & Discontinued Operations----------
Sarepta Therapeutics Net Income (Profit/Loss)
Average Shares used to compute Diluted EPS48.7M42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M
Average Shares used to compute Basic EPS48.7M42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M
Income Before Nonrecurring Items-262.7M-220.03M-133M-89.19M-29.35M-2.32M-32.17M-25.16M-23.95M-27.17M
Income from Nonrecurring Items-4.56M--2.79M-22.79M-91.94M-----
Sarepta Therapeutics Earnings Per Share Basic Net
Sarepta Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-5.40-5.20-3.32-2.64-1.24-0.12-1.74-1.62-2.04-3.00
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Income statement for another ticker

Before investing one should read a report on Sarepta Therapeutics stock analysis. It helps to look at the following income statement items:
  • Topline: A growing topline, as seen from the Sarepta Therapeutics revenue chart, as is the case with Sarepta Therapeutics indicates a growing business. One needs to compare the QoQ or YoY topline growth of SRPT stock with its peers like BPMC stock and HALO stock to see if the growth compares well with what can be expected for a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-267.26M for Sarepta Therapeutics for 2016. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.
The income statement is also called the profit and loss statement. Apart from the income statement, one can check the Sarepta Therapeutics historical stock prices to check how the price has moved with time. .

Sarepta Therapeutics Income Statement - Key Financial Ratios

Operating margin
Net profit margin

Annual Income Statements - Sarepta Therapeutics Inc Industry Peers

Aviragen Therapeutics income statement, BioCryst Pharma income statement, Blueprint Medicines income statement, Gilead Sciences income statement, Halozyme Therapeutics income statement